aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2024. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Founded in San Diego, Biosplice Therapeutics focuses on pioneering tissue regeneration and solutions for degenerative diseases through Wnt pathway modulation. Their core mission is to restore health by delivering first-in-class therapies that harness alternative splicing, addressing unmet medical needs in regenerative medicine and oncology. The company develops therapeutics aimed at conditions like osteoarthritis, where no drugs currently arrest disease progression, and seeks to overcome the diversity and adaptability of lethal cancers.
Biosplice Therapeutics has garnered attention for its innovative approach and significant potential impact on medical treatments. Notable affiliated individuals include key researchers and scientists specializing in molecular biology and regenerative medicine. The company has achieved milestones in preclinical and clinical trials, demonstrating promising results in tissue regeneration and cancer therapy. Their work has the potential to revolutionize treatment paradigms, offering hope to millions of patients suffering from currently untreatable conditions.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Therapeutics, Drug Development
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software, Therapeutics
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise
Geographic Exposure
United States
When was Biosplice Therapeutics founded?
Biosplice Therapeutics was founded in 2008.
Where is Biosplice Therapeutics’s headquarters located?
Biosplice Therapeutics’s headquarters is located in San Francisco, CA, US.
When was Biosplice Therapeutics’s last funding round?
Biosplice Therapeutics’s most recent funding round was for $120M (USD) in April 2021.
How many employees does Biosplice Therapeutics have?
Biosplice Therapeutics has 63 employees as of Feb 5, 2024.
How much has Biosplice Therapeutics raised to-date?
As of July 05, 2023, Biosplice Therapeutics has raised a total of $778M (USD) since Apr 15, 2021.
Add Comparison
Total Raised to Date
$778M
USD
Last Update Apr 15, 2021
Last Deal Details
$120M
USD
Apr 15, 2021
Series Unknown
Total Employees Over Time
63
As of Feb 2024
Biosplice Therapeutics Address
9360 Towne Centre Drive
San Francisco,
California
92121
United States of America
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts